Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
07 03 2023
07 03 2023
Historique:
received:
22
10
2022
revised:
06
12
2022
accepted:
11
12
2022
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
28
3
2023
Statut:
ppublish
Résumé
The causal pathway between complications after pancreatic cancer resection and impaired long-term survival remains unknown. The aim of this study was to investigate the impact of complications after pancreatic cancer resection on disease-free interval and overall survival, with adjuvant chemotherapy as a mediator. This observational study included all patients undergoing pancreatic cancer resection in the Netherlands (2014-2017). Clinical data were extracted from the prospective Dutch Pancreatic Cancer Audit. Recurrence and survival data were collected additionally. In causal mediation analysis, direct and indirect effect estimates via adjuvant chemotherapy were calculated. In total, 1071 patients were included. Major complications (hazards ratio 1.22 (95 per cent c.i. 1.04 to 1.43); P = 0.015 and hazards ratio 1.25 (95 per cent c.i. 1.08 to 1.46); P = 0.003) and organ failure (hazards ratio 1.86 (95 per cent c.i. 1.32 to 2.62); P < 0.001 and hazards ratio 1.89 (95 per cent c.i. 1.36 to 2.63); P < 0.001) were associated with shorter disease-free interval and overall survival respectively. The effects of major complications and organ failure on disease-free interval (-1.71 (95 per cent c.i. -2.27 to -1.05) and -3.05 (95 per cent c.i. -4.03 to -1.80) respectively) and overall survival (-1.92 (95 per cent c.i. -2.60 to -1.16) and -3.49 (95 per cent c.i. -4.84 to -2.03) respectively) were mediated by adjuvant chemotherapy. Additionally, organ failure directly affected disease-free interval (-5.38 (95 per cent c.i. -9.27 to -1.94)) and overall survival (-6.32 (95 per cent c.i. -10.43 to -1.99)). In subgroup analyses, the association was found in patients undergoing pancreaticoduodenectomy, but not in patients undergoing distal pancreatectomy. Major complications, including organ failure, negatively impact survival in patients after pancreatic cancer resection, largely mediated by adjuvant chemotherapy. Prevention or adequate treatment of complications and use of neoadjuvant treatment may improve oncological outcomes.
Sections du résumé
BACKGROUND
The causal pathway between complications after pancreatic cancer resection and impaired long-term survival remains unknown. The aim of this study was to investigate the impact of complications after pancreatic cancer resection on disease-free interval and overall survival, with adjuvant chemotherapy as a mediator.
METHODS
This observational study included all patients undergoing pancreatic cancer resection in the Netherlands (2014-2017). Clinical data were extracted from the prospective Dutch Pancreatic Cancer Audit. Recurrence and survival data were collected additionally. In causal mediation analysis, direct and indirect effect estimates via adjuvant chemotherapy were calculated.
RESULTS
In total, 1071 patients were included. Major complications (hazards ratio 1.22 (95 per cent c.i. 1.04 to 1.43); P = 0.015 and hazards ratio 1.25 (95 per cent c.i. 1.08 to 1.46); P = 0.003) and organ failure (hazards ratio 1.86 (95 per cent c.i. 1.32 to 2.62); P < 0.001 and hazards ratio 1.89 (95 per cent c.i. 1.36 to 2.63); P < 0.001) were associated with shorter disease-free interval and overall survival respectively. The effects of major complications and organ failure on disease-free interval (-1.71 (95 per cent c.i. -2.27 to -1.05) and -3.05 (95 per cent c.i. -4.03 to -1.80) respectively) and overall survival (-1.92 (95 per cent c.i. -2.60 to -1.16) and -3.49 (95 per cent c.i. -4.84 to -2.03) respectively) were mediated by adjuvant chemotherapy. Additionally, organ failure directly affected disease-free interval (-5.38 (95 per cent c.i. -9.27 to -1.94)) and overall survival (-6.32 (95 per cent c.i. -10.43 to -1.99)). In subgroup analyses, the association was found in patients undergoing pancreaticoduodenectomy, but not in patients undergoing distal pancreatectomy.
CONCLUSION
Major complications, including organ failure, negatively impact survival in patients after pancreatic cancer resection, largely mediated by adjuvant chemotherapy. Prevention or adequate treatment of complications and use of neoadjuvant treatment may improve oncological outcomes.
Identifiants
pubmed: 36959099
pii: 7085021
doi: 10.1093/bjsopen/zrac174
pmc: PMC10036251
pii:
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
Surg Today. 2008;38(7):579-84
pubmed: 18612780
Br J Surg. 2005 Sep;92(9):1150-4
pubmed: 16035134
JAMA Surg. 2019 Nov 1;154(11):1038-1048
pubmed: 31483448
Eur J Surg Oncol. 2018 Jul;44(7):1078-1082
pubmed: 29685757
J Cancer Res Clin Oncol. 2021 Sep;147(9):2609-2619
pubmed: 34115241
Ann Surg Oncol. 2013 May;20(5):1575-83
pubmed: 23076557
Surgeon. 2020 Feb;18(1):24-30
pubmed: 31466841
Br J Surg. 2021 Mar 12;108(2):188-195
pubmed: 33711145
HPB (Oxford). 2021 Nov;23(11):1666-1673
pubmed: 33934960
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
Ann Surg. 2022 Feb 1;275(2):e299-e306
pubmed: 33443905
Psychol Methods. 2013 Jun;18(2):137-50
pubmed: 23379553
World J Surg. 2013 Aug;37(8):1901-8
pubmed: 23564215
Lancet Oncol. 2022 Mar;23(3):328-330
pubmed: 35240080
J Clin Med. 2021 Dec 10;10(24):
pubmed: 34945079
HPB (Oxford). 2020 Feb;22(2):233-240
pubmed: 31439478
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Ann Surg. 2014 Aug;260(2):372-7
pubmed: 24374509
Psychol Methods. 2014 Dec;19(4):459-81
pubmed: 24885338
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):474-81
pubmed: 25308357
Arch Surg. 2008 May;143(5):476-81
pubmed: 18490557
Arch Surg. 2002 May;137(5):590-9
pubmed: 11982474
Br J Cancer. 1999 Mar;79(9-10):1392-8
pubmed: 10188881
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572951
Curr Opin Crit Care. 2017 Apr;23(2):159-166
pubmed: 28107224
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
J Gastrointest Surg. 2020 Jul;24(7):1581-1589
pubmed: 32410174
Anesthesiology. 2019 Aug;131(2):426-437
pubmed: 30860985
Ann Surg. 2016 Mar;263(3):440-9
pubmed: 26135690
Ann Surg. 2018 May;267(5):936-945
pubmed: 28338509
Epidemiology. 2011 Jul;22(4):582-5
pubmed: 21642779
Ann Surg Oncol. 2012 Mar;19(3):856-63
pubmed: 21879265
Surgery. 2016 Oct;160(4):987-996
pubmed: 27545992
Ann Surg. 2008 Jan;247(1):71-6
pubmed: 18156925
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
JAMA Surg. 2020 May 1;155(5):389-394
pubmed: 32129815
JAMA Surg. 2019 Oct 1;154(10):943-951
pubmed: 31411659
Ned Tijdschr Geneeskd. 2019 Jun 19;163:
pubmed: 31283118
J Clin Oncol. 2014 Feb 20;32(6):504-12
pubmed: 24419109
Lancet. 2022 May 14;399(10338):1867-1875
pubmed: 35490691
Ann Surg. 2022 Apr 1;275(4):769-775
pubmed: 32773631
JAMA Oncol. 2020 Nov 01;6(11):1733-1740
pubmed: 32910170
Cancer Chemother Pharmacol. 2013 Feb;71(2):419-29
pubmed: 23178955
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394
pubmed: 34366611
Bull World Health Organ. 2007 Nov;85(11):867-72
pubmed: 18038077
J Clin Epidemiol. 2006 Oct;59(10):1087-91
pubmed: 16980149
N Engl J Med. 2021 Oct 7;385(15):1345-1348
pubmed: 34596980